We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
解鎖市場時間軸與訊號動態
過去 90 日內有 119 個訊號。
此公司進入各市場的次序 — 由最舊至最新
21 active postings
11 active postings
註冊以查看完整訊號動態
Eli Lilly And Company 的國際擴張與競爭對手的比較
Eli Lilly And Company你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Eli Lilly And Company你 | 33 | 2 | -19% | 94 | 44 |
Pharmareferent (m/w/d) – Gastroenterologie, Region Aachen, Bonn, Düsseldorf, Neuss, Ratingen, Mönchengladbach, Remscheid, Wuppertal, Gummersbach, Arnsberg, Lüdenscheid
查看招聘Bad Homburg, Hesse, Germany · 2星期前
Associate Director- Legal
查看招聘Gurgaon, Haryana, India · 前日
Executive Director - Clinical Research Physician - GPS Medical
查看招聘São Paulo, São Paulo, Brazil · 3日前
New study on keeping weight off
進行中Losing weight, keeping it off
進行中
New study on keeping weight off
進行中禮來LIBRETTO-432三期研究顯示,塞普替尼使RET融合陽性非小細胞肺癌患者疾病復發或死亡風險降低83%。中國研究中心完成近半數全球入組,有望率先遞交上市申請。
FirstBio Therapeutics成立科學諮詢委員會,由全球製藥研發領導者組成,推進FB849免疫療法和神經退化性疾病管線開發。
康霈生技於ADA 2026發表CBL-514動物實驗數據,顯示與GLP-1/RA類藥物併用可將復胖率降低2.7倍,肝臟脂肪額外減少106.7%。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Eli Lilly And Company 業務、市場及增長訊號的快速解答。
